1. Home
  2. PMN vs UNCY Comparison

PMN vs UNCY Comparison

Compare PMN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$9.01

Market Cap

23.5M

Sector

Health Care

ML Signal

N/A

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

N/A

Current Price

$5.45

Market Cap

126.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMN
UNCY
Founded
2004
2016
Country
Canada
United States
Employees
N/A
22
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.5M
126.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PMN
UNCY
Price
$9.01
$5.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$72.67
$44.50
AVG Volume (30 Days)
43.4K
350.7K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.27
$3.71
52 Week High
$39.75
$11.00

Technical Indicators

Market Signals
Indicator
PMN
UNCY
Relative Strength Index (RSI) 83.68 44.20
Support Level $7.35 $6.31
Resistance Level $9.42 $6.95
Average True Range (ATR) 0.68 0.41
MACD 0.18 -0.12
Stochastic Oscillator 86.35 4.26

Price Performance

Historical Comparison
PMN
UNCY

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: